ES2739546T3 - Compuestos de fenotiazina para tratar el deterioro cognitivo leve - Google Patents

Compuestos de fenotiazina para tratar el deterioro cognitivo leve Download PDF

Info

Publication number
ES2739546T3
ES2739546T3 ES08762390T ES08762390T ES2739546T3 ES 2739546 T3 ES2739546 T3 ES 2739546T3 ES 08762390 T ES08762390 T ES 08762390T ES 08762390 T ES08762390 T ES 08762390T ES 2739546 T3 ES2739546 T3 ES 2739546T3
Authority
ES
Spain
Prior art keywords
unsubstituted
substituted
alkyl
aliphatic
carboaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08762390T
Other languages
English (en)
Spanish (es)
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Application granted granted Critical
Publication of ES2739546T3 publication Critical patent/ES2739546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08762390T 2007-06-19 2008-06-17 Compuestos de fenotiazina para tratar el deterioro cognitivo leve Active ES2739546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
ES2739546T3 true ES2739546T3 (es) 2020-01-31

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08762390T Active ES2739546T3 (es) 2007-06-19 2008-06-17 Compuestos de fenotiazina para tratar el deterioro cognitivo leve

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2205245T3 (en) * 2007-10-03 2015-09-28 Wista Lab Ltd Therapeutic use of diaminophenothiaziner
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
EP3686181B1 (en) * 2013-01-30 2024-07-17 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
DK3258938T3 (da) * 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US20070037848A1 (en) * 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
ES2409683T3 (es) * 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2001556T3 (da) * 2006-03-29 2014-11-10 Wista Lab Ltd Thioninium-forbindelser og anvendelse deraf
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN101511803B (zh) * 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法

Also Published As

Publication number Publication date
US20100184752A1 (en) 2010-07-22
HUE045460T2 (hu) 2019-12-30
CA2690746A1 (en) 2008-12-24
MY177001A (en) 2020-09-01
WO2008155533A3 (en) 2009-02-19
PT2167095T (pt) 2019-08-06
US9211294B2 (en) 2015-12-15
CN101820884A (zh) 2010-09-01
AU2008265045B2 (en) 2014-02-27
EP2167095A2 (en) 2010-03-31
JP2010530403A (ja) 2010-09-09
DK2167095T3 (da) 2019-07-29
SI2167095T1 (sl) 2019-09-30
CA2690746C (en) 2018-01-02
HRP20191513T1 (hr) 2019-11-29
AU2008265045A1 (en) 2008-12-24
CN101820884B (zh) 2013-08-28
PL2167095T3 (pl) 2019-11-29
WO2008155533A2 (en) 2008-12-24
JP5725605B2 (ja) 2015-05-27
EP2167095B1 (en) 2019-05-29
BRPI0813670A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
AU2008265045B2 (en) Phenothiazine compounds for treating Mild Cognitive Impairment
ES2675544T3 (es) Tratamiento para trastornos mentales y neurológicos
ES2701089T3 (es) Uso terapéutico de las diaminofenotiazinas
ES2881081T3 (es) Procedimientos y composiciones para mejorar la función cognitiva
ES2952672T3 (es) Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia
ES2948263T3 (es) Uso del ácido (S)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxílico y compuestos relacionados, ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico en el tratamiento del síndrome del X frágil o del síndrome de temblor/ataxia asociado al X frágil
ES2886873T3 (es) Composiciones farmacéuticas para mejorar el rendimiento de la memoria
US20230310488A1 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
US20110217387A1 (en) Pharmaceutical composition for treatment of fibromyalgia
ITRM960360A1 (it) Farmaco a base di un derivato della carnitina per il trattamento del= la demenza di alzheimer in pazienti ad insorgenza precoce della pato=
ES2949288T3 (es) Uso de un inhibidor de acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con enfermedad de Parkinson
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
CN114072154B (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
BR112020016672A2 (pt) Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo
ES2747993T3 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
EP4587008A1 (en) Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine
ES2355393T3 (es) Memantina para el tratamiento de la enfermedad de alzehimer de leve a moderada.
ES2340399T3 (es) Uso de neboglamina para el tratamiento de la esquizofrenia.
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
CA3034187A1 (en) Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
BRPI1015509A2 (pt) Tratamento da dor aguda, não traumática, utilizando uma combinação de diclofenaco-colestiramina, uridina, citidina e hidroxocobalamina